Viveve Medical (VIVE) 10-Q 12 Nov 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 10, 2020
Document Information [Line Items]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	0000879682
Trading Symbol	vive
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		21,653,782
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 9,200,000	$ 13,308,000	[1]
Accounts receivable, net of allowance for doubtful accounts of $566 and $407 as of September 30, 2020 and December 31, 2019, respectively	689,000	1,573,000	[1]
Inventory	4,591,000	4,861,000	[1]
Prepaid expenses and other current assets	1,764,000	2,447,000	[1]
Total current assets	16,244,000	22,189,000	[1]
Property and equipment, net	2,507,000	3,046,000	[1]
Investment in limited liability company	893,000	1,216,000	[1]
Other assets	282,000	526,000	[1]
Total assets	19,926,000	26,977,000	[1]
Current liabilities:
Accounts payable	695,000	1,608,000	[1]
Accrued liabilities	1,990,000	4,698,000	[1]
Paycheck Protection Program loan, current portion	664,000
Total current liabilities	3,349,000	6,306,000	[1]
Note payable, noncurrent portion	4,377,000	3,983,000	[1]
Paycheck Protection Program loan, noncurrent portion	679,000
Other noncurrent liabilities	432,000	167,000	[1]
Total liabilities	8,837,000	10,456,000	[1]
Commitments and contingences (Note 9)
Stockholders’ equity:
Common stock, $0.0001 par value; 75,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 21,653,782 and 7,075,684 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	2,000	1,000	[1]
Additional paid-in capital	226,158,000	214,431,000	[1]
Accumulated deficit	(215,071,000)	(197,911,000)	[1]
Total stockholders’ equity	11,089,000	16,521,000	[1]
Total liabilities and stockholders’ equity	19,926,000	26,977,000	[1]
Series A Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock
Series B Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock			[1]
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accounts receivable, allowance for doubtful accounts	$ 566	$ 407	[1]
Convertible preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	[1]
Common stock, shares authorized (in shares)	75,000,000	75,000,000	[1]
Common stock, shares issued (in shares)	21,653,782	7,075,684	[1]
Common stock, shares outstanding (in shares)	21,653,782	7,075,684	[1]
Series A Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares issued (in shares)	0	1,852,173
Convertible preferred stock, shares outstanding (in shares)	0	1,852,173
Series B Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	[1]
Convertible preferred stock, shares issued (in shares)	34,735	31,678	[1]
Convertible preferred stock, shares outstanding (in shares)	34,735	31,678	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue	$ 1,524,000	$ 1,052,000	$ 3,532,000	$ 5,116,000
Cost of revenue	1,283,000	1,099,000	3,483,000	3,981,000
Gross profit (loss)	241,000	(47,000)	49,000	1,135,000
Operating expenses:
Research and development	884,000	1,449,000	3,745,000	6,831,000
Selling, general and administrative	2,761,000	5,032,000	10,476,000	17,188,000
Restructuring costs				742,000
Total operating expenses	3,645,000	6,481,000	14,221,000	24,761,000
Loss from operations	(3,404,000)	(6,528,000)	(14,172,000)	(23,626,000)
Modification of Series A and B warrants			(1,838,000)
Interest expense, net	(235,000)	(1,209,000)	(668,000)	(3,519,000)
Other expense, net	(41,000)	(51,000)	(159,000)	(133,000)
Net loss from consolidated companies	(3,680,000)	(7,788,000)	(16,837,000)	(27,278,000)
Loss from minority interest in limited liability company	(55,000)	(168,000)	(323,000)	(431,000)
Comprehensive and net loss	(3,735,000)	(7,956,000)	(17,160,000)	(27,709,000)
Series B convertible preferred stock dividends	(1,053,000)		(3,064,000)
Net loss attributable to common stockholders	$ (4,788,000)	$ (7,956,000)	$ (20,224,000)	$ (27,709,000)
Net loss per share of common stock:
Basic and diluted (in dollars per share)	$ (0.26)	$ (13.51)	$ (1.47)	$ (54.73)
Weighted average shares used in computing net loss per common share:
Basic and diluted (in shares)	18,079,200	588,976	13,747,913	506,329

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	November 2019 Offering [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	November 2019 Offering [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	November 2019 Offering [Member]Common Stock [Member]	November 2019 Offering [Member]Additional Paid-in Capital [Member]	November 2019 Offering [Member]Retained Earnings [Member]	November 2019 Offering [Member]	Purchase Agreement with LPC [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Purchase Agreement with LPC [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Purchase Agreement with LPC [Member]Common Stock [Member]	Purchase Agreement with LPC [Member]Additional Paid-in Capital [Member]	Purchase Agreement with LPC [Member]Retained Earnings [Member]	Purchase Agreement with LPC [Member]	Series A Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Series A Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Series A Warrants [Member]Common Stock [Member]	Series A Warrants [Member]Additional Paid-in Capital [Member]	Series A Warrants [Member]Retained Earnings [Member]	Series A Warrants [Member]	Series B Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Series B Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Series B Warrants [Member]Common Stock [Member]	Series B Warrants [Member]Additional Paid-in Capital [Member]	Series B Warrants [Member]Retained Earnings [Member]	Series B Warrants [Member]	Series A-2 Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Series A-2 Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Series A-2 Warrants [Member]Common Stock [Member]	Series A-2 Warrants [Member]Additional Paid-in Capital [Member]	Series A-2 Warrants [Member]Retained Earnings [Member]	Series A-2 Warrants [Member]	Series B-2 Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Series B-2 Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Series B-2 Warrants [Member]Common Stock [Member]	Series B-2 Warrants [Member]Additional Paid-in Capital [Member]	Series B-2 Warrants [Member]Retained Earnings [Member]	Series B-2 Warrants [Member]	Director [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Director [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Director [Member]Common Stock [Member]	Director [Member]Additional Paid-in Capital [Member]	Director [Member]Retained Earnings [Member]	Director [Member]	Consultant [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Consultant [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Consultant [Member]Common Stock [Member]	Consultant [Member]Additional Paid-in Capital [Member]	Consultant [Member]Retained Earnings [Member]	Consultant [Member]	Employees [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Employees [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Employees [Member]Common Stock [Member]	Employees [Member]Additional Paid-in Capital [Member]	Employees [Member]Retained Earnings [Member]	Employees [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]	Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Total
Balances (in shares) at Dec. 31, 2018																																																									463,630
Balances at Dec. 31, 2018																																																										$ 160,297	$ (155,385)			$ 4,912
Stock-based compensation expense																																																										470				470
Issuance of common shares from employee stock purchase plan (in shares)																																																									429
Issuance of common shares from employee stock purchase plan																																																										35				35
Issuance of restricted common shares in connection with consulting agreement (in shares)																																																									274
Issuance of restricted common shares in connection with consulting agreement																																																										25				25
Net loss																																																											(10,029)			(10,029)
Restricted stock awards (in shares)																																																									6
Restricted stock awards																																																										1				1
Stock-based compensation expense																																																										470				470
Balances (in shares) at Mar. 31, 2019																																																									464,339
Balances at Mar. 31, 2019																																																										160,828	(165,414)			(4,586)
Balances (in shares) at Dec. 31, 2018																																																									463,630
Balances at Dec. 31, 2018																																																										160,297	(155,385)			4,912
Net loss																																																														(27,709)
Balances (in shares) at Sep. 30, 2019																																																									1,469,789
Balances at Sep. 30, 2019																																																										168,304	(183,094)			(14,790)
Balances (in shares) at Dec. 31, 2018																																																									463,630
Balances at Dec. 31, 2018																																																										160,297	(155,385)			4,912
Series B convertible preferred stock dividends paid in PIK shares (in shares)																																																													378
Balances (in shares) at Dec. 31, 2019																																																							1,852,173	31,678	7,075,684
Balances at Dec. 31, 2019																																																									$ 1	214,431	(197,911)			16,521	[1]
Balances (in shares) at Mar. 31, 2019																																																									464,339
Balances at Mar. 31, 2019																																																										160,828	(165,414)			(4,586)
Stock-based compensation expense																																																										562				562
Issuance of common shares from employee stock purchase plan (in shares)																																																									602
Issuance of common shares from employee stock purchase plan																																																										20				20
Net loss																																																											(9,724)			(9,724)
Restricted stock awards (in shares)																																							525						250						6
Restricted stock awards																																								$ 48		$ 48				$ 11		$ 11
Stock-based compensation expense																																																										562				562
Balances (in shares) at Jun. 30, 2019																																																									465,722
Balances at Jun. 30, 2019																																																										161,469	(175,138)			(13,669)
Stock-based compensation expense																																																										503				503
Issuance of common shares from employee stock purchase plan (in shares)																																																									200
Issuance of common shares from employee stock purchase plan																																																										1				1
Net loss																																																											(7,956)			(7,956)
Issuance of initial purchase common shares under the Purchase Agreement with LPC (in shares)																																																									1,004,171
Issuance of initial purchase common shares under the Purchase Agreement with LPC																																																										6,322				6,322
Restricted stock awards (in shares)																																							378												4
Restricted stock awards																																								14		14
Stock-based compensation expense																																																										503				503
Reverse stock split - cancellation and payout of fractional shares (in shares)																																																									(686)
Reverse stock split - cancellation and payout of fractional shares																																																										(5)				(5)
Balances (in shares) at Sep. 30, 2019																																																									1,469,789
Balances at Sep. 30, 2019																																																										168,304	(183,094)			(14,790)
Balances (in shares) at Dec. 31, 2019																																																							1,852,173	31,678	7,075,684
Balances at Dec. 31, 2019																																																									$ 1	214,431	(197,911)			16,521	[1]
Issuance costs				$ (30)		$ (30)
Conversion of Series A convertible preferred stock into common stock (in shares)																																																							(1,852,173)		1,852,173
Conversion of Series A convertible preferred stock into common stock
Issuance of common shares in connection with warrant exercises (in shares)															1,026,240						45,473
Issuance of common shares in connection with warrant exercises																$ 1,591		$ 1,591				$ 70		$ 70
Series B convertible preferred stock dividends																																																										(990)				(990)
Series B convertible preferred stock dividends paid in PIK shares (in shares)																																																								989
Series B convertible preferred stock dividends paid in PIK shares																																																										989				989
Stock-based compensation expense																																																										686				686
Issuance of common shares from employee stock purchase plan (in shares)																																																									320
Issuance of common shares from employee stock purchase plan
Issuance of restricted common shares in connection with consulting agreement (in shares)																																																									28,313
Issuance of restricted common shares in connection with consulting agreement																																																										24				24
Net loss																																																											(6,310)			(6,310)
Stock-based compensation expense																																																										686				686
Balances (in shares) at Mar. 31, 2020																																																								32,667	10,028,203
Balances at Mar. 31, 2020																																																									$ 1	216,771	(204,221)			12,551
Balances (in shares) at Dec. 31, 2019																																																							1,852,173	31,678	7,075,684
Balances at Dec. 31, 2019																																																									$ 1	214,431	(197,911)			16,521	[1]
Issuance of common shares in connection with warrant exercises (in shares)																														3,928,284						203,800
Series B convertible preferred stock dividends paid in PIK shares (in shares)																																																													3,057
Net loss																																																														(17,160)
Issuance of initial purchase common shares under the Purchase Agreement with LPC (in shares)																																																												5,473,410
Balances (in shares) at Sep. 30, 2020																																																								34,735	21,653,782
Balances at Sep. 30, 2020																																																									$ 2	226,158	(215,071)			11,089
Balances (in shares) at Mar. 31, 2020																																																								32,667	10,028,203
Balances at Mar. 31, 2020																																																									$ 1	216,771	(204,221)			12,551
Issuance costs				$ (3)		$ (3)				$ (452)		$ (452)
Issuance of common shares in connection with warrant exercises (in shares)															4,852,284						293,490
Issuance of common shares in connection with warrant exercises															$ 1	2,959		2,960				179		179
Series B convertible preferred stock dividends																																																										(1,021)				(1,021)
Series B convertible preferred stock dividends paid in PIK shares (in shares)																																																								1,018
Series B convertible preferred stock dividends paid in PIK shares																																																										1,018				1,018
Stock-based compensation expense																																																										632				632
Issuance of common shares from employee stock purchase plan (in shares)																																																									300
Issuance of common shares from employee stock purchase plan
Issuance of restricted common shares in connection with consulting agreement (in shares)																																																									34,531
Issuance of restricted common shares in connection with consulting agreement																																																										25				25
Net loss																																																											(7,115)			(7,115)
Modification of warrants in connection with 2020 Warrant Offering																997		997				841		841
Issuance of Series A-2 and B-2 warrants in connection with 2020 Warrant Offering																																																										1,838				1,838
Issuance costs for Series A-2 and B-2 warrants in connection with 2020 Warrant Offering																																																										(1,838)				(1,838)
Transaction costs in connection with 2020 Warrant Offering																																																										(326)				(326)
Issuance of initial purchase common shares under the Purchase Agreement with LPC (in shares)																																																									525,000
Issuance of initial purchase common shares under the Purchase Agreement with LPC																																																										341				341
Restricted stock awards (in shares)																																																									250
Restricted stock awards
Stock-based compensation expense																																																										632				632
Balances (in shares) at Jun. 30, 2020																																																								33,685	15,734,058
Balances at Jun. 30, 2020																																																									$ 2	221,961	(211,336)			10,627
Issuance costs										$ (42)		$ (42)
Issuance of common shares in connection with warrant exercises (in shares)															1,117,020						3,824,104						892,300						38,990
Issuance of common shares in connection with warrant exercises																$ 681		$ 681				$ 2,333		$ 2,333				$ 568		$ 568				$ 25		$ 25
Series B convertible preferred stock dividends																																																										(1,053)				(1,053)
Series B convertible preferred stock dividends paid in PIK shares (in shares)																																																								1,050					1,050
Series B convertible preferred stock dividends paid in PIK shares																																																										1,050				1,050
Stock-based compensation expense																																																										617				617
Net loss																																																											(3,735)			(3,735)
Transaction costs in connection with 2020 Warrant Offering																																																										(7)				(7)
Restricted stock awards (in shares)																																							220												47,090
Restricted stock awards																																																				$ 25		$ 25
Stock-based compensation expense																																																										617				617
Balances (in shares) at Sep. 30, 2020																																																								34,735	21,653,782
Balances at Sep. 30, 2020																																																									$ 2	$ 226,158	$ (215,071)			$ 11,089
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (17,160,000)	$ (27,709,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts and write off of accounts receivable	335,000	260,000
Depreciation and amortization	965,000	819,000
Stock-based compensation	2,009,000	1,634,000
Non-cash interest expense	394,000	1,266,000
Amortization of operating lease right-of-use assets and accretion of operating lease liabilities	3,000	4,000
Loss from minority interest in limited liability company	323,000	431,000
Loss on disposal of property and equipment	14,000	93,000
Modification of Series A and B warrants	1,838,000
Changes in assets and liabilities:
Accounts receivable	549,000	2,638,000
Inventory	233,000	(236,000)
Prepaid expenses and other current assets	683,000	(493,000)
Other noncurrent assets	444,000	40,000
Accounts payable	(913,000)	(2,203,000)
Accrued and other liabilities	(2,918,000)	(2,566,000)
Other noncurrent liabilities	265,000	160,000
Net cash used in operating activities	(12,936,000)	(25,862,000)
Cash flows from investing activities:
Purchase of property and equipment	(403,000)	(848,000)
Net cash used in investing activities	(403,000)	(848,000)
Cash flows from financing activities:
Proceeds from exercise of common warrants	8,407,000
Transaction costs in connection with 2020 Warrant Offering	(333,000)
Proceeds from Paycheck Protection Program loan	1,343,000
Proceeds from intial purchase of common shares under Purchase Agreement with LPC	341,000
Proceeds from sale of common shares, net of issuance cost		6,322,000
Proceeds from issuance of common shares from employee stock purchase plan		56,000
Transaction costs in connection with note payable		(100,000)
Reverse stock split - cancellation and payout of fractional shares		(5,000)
Net cash provided by financing activities	9,231,000	6,273,000
Net decrease in cash and cash equivalents	(4,108,000)	(20,437,000)
Cash and cash equivalents - beginning of period	13,308,000	29,523,000
Cash and cash equivalents - end of period	9,200,000	9,086,000
Supplemental disclosure:
Cash paid for interest		2,067,000
Cash paid for income taxes
Supplemental disclosure of cash flow information as of end of period:
Issuance of Series B convertible preferred stock in settlement of dividends	3,057,000
Issuance of note payable in settlement of accrued interest	392,000	973,000
Net transfer of equipment between inventory and property and equipment	37,000	214,000
Operating cash outflows from operating leases	226,000	220,000
Right-of-use assets obtained in exchange for operating lease liabilities (upon adoption of ASC 842)		629,000
November 2019 Offering [Member]
Cash flows from financing activities:
Transaction costs in connection with November 2019 Offering	(33,000)
Purchase Agreement with LPC [Member]
Cash flows from financing activities:
Transaction costs in connection with November 2019 Offering	$ (494,000)

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) designs, develops, manufactures and markets a platform medical technology, which we refer to as Cryogen-cooled Monopolar RadioFrequency Purchase Agreement with Lincoln Park Capital, LLC On June 8, 2020, $10,000,000 30 On June 9, 2020, 525,000 $0.65 may 250,000 500,000 11 no Other than as described above and Note 11 no 2020 On April 15, 2020, $1.55 $0.61 April 16, 2020, 4,820,584 242,790 $3,089,000. 2 4,820,584 2 242,790 $0.6371 five April 20, 2020. 2020 $333,000. 11 2 2 September 30, 2020, 2 3,928,284 2 203,800 2019 In November 2019, “November 2019 $11,500,000, $9,922,000. A total of 1,945,943 5,473,410 7,419,353 7,419,353 September 30, 2020, no September 30, 2020, 423,809 3,256,286 10 11 In connection with the closing of the November 2019 $28,981,000 $31,300,000, 31,300 9,893,776 September 30, 2020, 34,735 9,893,776 6 Interim Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 03 X. not The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10 December 31, 2019, March 19, 2020. nine September 30, 2020 not December 31, 2020 Liquidity and Management Plans The Company has adopted the Financial Accounting Standards Board's (“FASB”) Accounting Standard Codification (“ASC”) Topic 205 40, one The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. However, since inception, the Company has sustained significant operating losses and such losses are expected to continue for the foreseeable future. As of September 30, 2020, $215,071,000, $9,200,000 $12,895,000. $12,936,000 nine September 30, 2020. $9.2 nine September 30, 2020, $3.6 three September 30, 2020, November 2021. $9.7 To fund further operations, the Company will need to raise additional capital. The Company may no not no

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Reverse Stock Split The Company effected a 1 100 September 18, 2019. not No The par value of the Company's common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75,000,000. The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company's equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100 Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company's products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three September 30, 2020, one 40% three September 30, 2019, two 31% nine September 30, 2020, one 45% nine September 30, 2019, one 17% There were no 10% three nine September 30, 2020 2019. As of September 30, 2020, one 16% December 31, 2019, two 49% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $566,000 September 30, 2020 $407,000 December 31, 2019. There were no three September 30, 2020. nine September 30, 2020, $173,000 no three nine September 30, 2019. Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company's operating leases for the Viveve System generally have a rental period of six nine June 30, 2019. three September 30, 2020 2019, $471,000 $177,000, nine September 30, 2020 2019, $829,000 $177,000, September 30, 2020 December 31, 2019, $617,000 $662,000, three nine September 30, 2020, $197,000 $499,000, December 31, 2019. Late in the first 2020, 19 70 80% three 19 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No September 30, 2020 December 31, 2019. $0 $108,000, not September 30, 2020 December 31, 2019, three nine September 30, 2020, $21,000 $108,000, December 31, 2019. The following table reflects the changes in our customer contract liabilities for the nine September 30, 2020: September 30, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ - $ 108 $ (108 ) Total $ - $ 108 $ (108 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three nine September 30, 2020 2019, not Contract Costs The Company began its rental program in the quarter ended June 30, 2019. $55,000 $337,000 September 30, 2020 December 31, 2019, three September 30, 2020 2019, $58,000 $30,000, nine September 30, 2020 2019, $538,000 $30,000, no one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company's financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three nine September 30, 2020 2019 Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 United States $ 844 $ 652 $ 1,648 $ 3,106 Asia Pacific 680 373 1,865 1,684 Europe and Middle East - 27 5 316 Latin America - - 14 10 Total $ 1,524 $ 1,052 $ 3,532 $ 5,116 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee's business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three nine September 30, 2020 2019. Product Warranty The Company's products sold to customers are generally subject to warranties between one three not Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee's service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option's expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three nine September 30, 2020 2019, Net Loss per Share The Company's basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive: Nine Months Ended September 30, 2020 2019 Series B convertible preferred stock 22,702,614 (a) - Warrants to purchase common stock 17,710,876 5,549 Stock options to purchase common stock 9,755,454 50,471 Restricted common stock awards 2,217 3,432 (a) As of September 30, 2020, 34,735 22,702,614 1 653.59 $1,000 $1.53 not Recently Issued and Adopted Accounting Standards In November 2019, 2019 08, 718 606 718. December 15, 2019, January 1, 2020 not In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021, not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no September 30, 2020 December 31, 2019. The carrying amounts of the Company's financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of September 30, 2020, December 31, 2019 There were no

Note 4 - Investment in Limited

Note 4 - Investment in Limited Liability Company	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	4. Investment in Limited Liability Company On August 8, 2017, Under the terms of the Distributorship Agreement, ICM agreed to not third not three September 30, 2020 2019, 185 zero $26,000 $0, nine September 30, 2020 2019, 425 300 $46,000 $27,000, September 30, 2020, 5,225 $10,000 $0 three September 30, 2020 2019, $30,000 $27,000 nine September 30, 2020 2019, September 30, 2020, $16,000; no December 31, 2019. In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not September 30, 2020, 7% three three September 30, 2020 2019, $55,000 168,000, nine September 30, 2020 2019, $323,000 $431,000, In February 2019, no

Note 5 - Accrued Liabilities

Note 5 - Accrued Liabilities	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5. Accrued Liabilities Accrued liabilities consisted of the following as of September 30, 2020 December 31, 2019 ( September 30, December 31, 2020 2019 Deferred revenue - subscription rental program $ 617 $ 662 Accrued bonuses 589 726 Accrued payroll and other related expenses 335 839 Current operating lease liabilities 203 268 Accrued professional fees 133 592 Customer advances 21 53 Accrued sales commission 20 281 Accrued inventory - 474 Accrued interest 6 440 Customer contracts liabilities - 108 Other accruals 66 255 Total accrued liabilities $ 1,990 $ 4,698

Note 6 - Note Payable

Note 6 - Note Payable	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Note Payable On May 22, 2017, December 12, 2017 November 29, 2018 ( “2017 $20,000,000 $10,000,000 $30,000,000 December 29, 2017, $10,000,000 In connection with the 2017 two 10 2,220 $950.00 11 Under the 2017 November 12, 2019 six four 2017 12.5%, 4.0% may, three nine September 30, 2019, $331,000 $973,000, 5.0% As security for its obligations under the 2017 The terms of the 2017 2017 On November 12, 2019, 2017 No. 3” $28,981,000 $31,300,000. 31,300 9,893,776 5 120% $1.53 $1.836 11 one The Amendment No. 3 2017 ● repayment provisions were amended such that repayment is permitted only with, or after, the redemption in full of the Series B convertible preferred stock issued to CRG; ● the interest only payment period and the period during which the Company may 23rd first no 2017 ● modified certain of the covenants, including (i) to permit issuance of the Series B convertible preferred stock and any preferred stock issued in the equity financing and the exercise and performance by the Company of its rights and obligations in connection with such CRG preferred stock and any preferred stock issued in the equity financing, (ii) eliminate the Company's ability to enter into permitted acquisitions, (iii) further restrict the incurrence of additional indebtedness and removal of the equity cure right, and (iv) eliminate the minimum revenue requirement; and ● the back-end facility fee on the aggregate remaining principal balance on the term loan shall be increased from 5% 25%. During the three nine September 30, 2020, $136,000 $392,000, As of September 30, 2020, As of September 30, 2020 December 31, 2019, $4,377,000 $3,983,000, The Company accounted for the changes in the 2017 31,300 9,893,776 November 26, 2019 $1,023.23 $32,027,000 10 $3,502,000 11 $6,705,000, December 31, 2019. As of September 30, 2020, Year Ending December 31, 2020 (remaining 3 months) $ - 2021 - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,605 ) Present value of obligations 4,387 Less: Unamortized debt discount (10 ) Note payable, noncurrent portion $ 4,377

Note 7 - Paycheck Protection Pr

Note 7 - Paycheck Protection Program Loan	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Long-term Debt [Text Block]	7. Paycheck Protection Program Loan The Paycheck Protection Program (“PPP”) was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (“SBA”). On April 24, 2020, $1,343,000 1.00% two ten may No As of September 30, 2020, Year Ending December 31, 2020 (remaining 3 months) $ - 2021 938 2022 426 Total payments 1,364 Less: Amount representing interest (20 ) Present value of obligations 1,344 Paycheck Protection Program loan,current portion 664 Paycheck Protection Program loan, noncurrent portion $ 679

Note 8 - Leases

Note 8 - Leases	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	8. Leases Lessee: The following information pertains to those operating lease agreements where the Company is the lessee. On February 1, 2017, 12,400 January 26, 2017. June 1, 2017 May 2021. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 In September 2018, 36 September 20, 2018. $3,000. After the adoption of ASU 842 January 1, 2019, 12 not The following table reflects the Company's lease assets and lease liabilities at September 30, 2020 December 31, 2019 ( September 30, December 31, 2020 2019 Assets: Operating lease right-of-use assets $ 200 $ 395 Liabilities: Current operating lease liabilities $ 203 $ 268 Noncurrent operating lease liabilities - 132 $ 203 $ 400 The operating lease right-of-use assets are included in other assets on the condensed consolidated balance sheet. The operating lease liabilities are included in accrued liabilities and other noncurrent liabilities on the condensed consolidated balance sheet. The operating leases expense for the three September 30, 2020 2019 $77,000 $75,000, nine September 30, 2020 2019 $226,000 $225,000, As of September 30, 2020, Year Ending December 31, 2020 (remaining 3 months) $ 76 2021 137 Total lease payments 213 Less: Amount representing interest (10 ) Present value of lease liabilities $ 203 The weighted average remaining lease term was approximately 8 September 30, 2020. three September 30, 2020 12.5%. Lessor: The following information pertains to those operating lease agreements where the Company is the lessor. As of September 30, 2020, Year Ending December 31, 2020 (remaining 3 months) $ 381 2021 236 Thereafter - Total $ 617 As of September 30, 2020, $946,000 three nine September 30, 2020 $117,000 $345,000,

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. Commitments and Contingencies Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not

Note 10 - Preferred Stock

Note 10 - Preferred Stock	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Preferred Stock [Text Block]	10. Preferred Stock In connection with the closing of the public offering in November 2019, With certain exceptions, as described in the Series A Certificate of Designation, the shares of Series A preferred stock have no Each share of Series A convertible preferred stock is convertible at any time at the holder's option into one A total of 5,473,410 nine September 30, 2020 ● In January 2020, 1,183,151 ● In February 2020, 669,022 As of September 30, 2020, no As previously reported (see Note 6 31,300 9,893,776 November 26, 2019, 12.5% December 31, 2019, 378 $2,000 three September 30, 2020, 1,050 $3,000 nine September 30, 2020, 3,057 $7,000 September 30, 2020, 34,735 no The Series B convertible preferred stock provides that for so long as any shares are outstanding, the consent of the holders of the Series B convertible preferred stockholders would be required to amend the Company's organizational documents, approve any merger, sale of assets, or other major corporate transaction, or incur additional indebtedness, among other items. The fair value of the Series B convertible preferred stock was determined in connection with the CRG debt conversion as part of the accounting for that transaction as a troubled debt restructuring. Based on our valuation analysis, as of November 26, 2019, $1,023.23 $32,027,000 31,300 6 Under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not

Note 11 - Common Stock

Note 11 - Common Stock	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Common Stock Purchase Agreement with Lincoln Park Capital, LLC On June 8, 2020, $10,000,000 30 On June 9, 2020, 525,000 $0.65 may 250,000 may 300,000 not $1.00 may 500,000 not $2.00 may not $1,000,000. no In addition to Regular Purchases described above, the Company may not three 3 30% 95% Under certain circumstances and in accordance with the Purchase Agreement, the Company may Other than as described above, there are no Transaction costs in connection with the Purchase Agreement with LPC totaled approximately $494,000. $325,000. no 2019 In November 2019, “November 2019 $11,500,000, $9,922,000. The offering comprised of: ( 1 $1.55 one one $1.55 first one $1.55 fifth 2 $1.55 one one one $1.55 first one $1.55 fifth The securities comprising the units were immediately separable and were issued separately. A total of 1,945,943 5,473,410 7,419,353 7,419,353 As of September 30, 2020, no 10 As of September 30, 2020, 423,809 3,256,286 Warrants for Common Stock Restricted Common Shares The activity of restricted common shares during the nine September 30, 2020 ● In September 2020, 47,090 $25,000. ● In June 2020, 34,531 $25,000. ● In March 2020, 28,313 $24,000. Warrants for Common Stock As of September 30, 2020, Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 November 2019 Common Shares November 26, 2020 $ 0.61 423,809 November 2019 Common Shares November 26, 2024 $ 0.61 3,256,286 November 2019 Common Shares November 26, 2024 $ 1.836 9,893,776 April 2020 Common Shares April 21, 2025 $ 0.6371 4,132,084 17,710,876 In connection with the November 2019 7,419,353 7,419,353 one $1.55 first one $1.55 fifth one one $1.55 one five $1.55 In February 2020, 1,026,240 $1,591,000, 45,473 $70,000. On April 15, 2020, $1.55 $0.61 $0.61 $1.55 April 15, 2020, 718, 718 $1,838,000 Immediately Immediately before Modification After Modification Exercise price $1.55 $0.61 Common stock price $0.63 $0.63 Expected term (in years) 2.8 2.8 Average volatility 97% 97% Risk-free interest rate 0.27% 0.27% Dividend yield 0% 0% On April 16, 2020, 4,820,584 242,790 $3,089,000. In conjunction, the Company also agreed to issue new Series A- 2 4,820,584 2 242,790 $0.6371 five 2 2 $1,838,000 0%, 84.1%, 0.35% five 2 2 April 20, 2020. 2020 $333,000. In May 2020, 4,099 $2,500. In June 2020, 27,601 $17,000, 50,700 $31,000. In August 2020, 1,117,020 $681,000, 3,809,104 $2,324,000. In August 2020, 892,300 2 $569,000, 38,900 2 $25,000. In September 2020, 15,000 $9,000. As of September 30, 2020, 423,809 3,256,286 As of September 30, 2020, 2 3,928,284 2 203,800 In connection with the CRG Debt Conversion, CRG received warrants exercisable for 9,893,776 15% November 2019 five 120% $1.53 $1.836 $3,502,000 0%, 68.8%, 1.58% five In connection with the 2017 2,220, $950.00 ten $940,000 $790,000, three nine September 30, 2020, $1,000 $2,000, three nine September 30, 2019, $119,000 $202,000, September 30, 2020, $10,000. No three nine September 30, 2020 2019. A total of zero 215 three nine September 30, 2020, 859 three nine September 30, 2019.

Note 12 - Summary of Stock Opti

Note 12 - Summary of Stock Options	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards (“RSAs”) from two 2006 “2006 2013 “2013 As of September 30, 2020, 2006 104 no $992.00 2.3 As of September 30, 2020, 2013 9,755,350 4,770,640 $1.95 9.1 In January 2020, 2020 2013 2,639,926 11,872,531 14,512,457 January 1, 2020. Activity under the 2006 2013 Nine Months Ended September 30, 2020 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 10,087,678 $ 2.22 9.9 $ 3,928,715 Options granted 1,018,000 $ 0.70 Options exercised - Options canceled (1,350,224 ) $ 3.01 Options outstanding, end of period 9,755,454 $ 1.96 9.1 $ - Vested and exercisable and expected to vest, end of period 9,047,744 $ 2.03 9.1 $ - Vested and exercisable, end of period 1,969,073 $ 5.19 8.7 $ - The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company's closing share price as of September 30, 2020. The options outstanding and exercisable as of September 30, 2020 Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices September 30, 2020 Price Term (Years) September 30, 2020 Price $0.52 - $0.89 9,563,606 $ 0.85 9.1 1,918,010 $ 0.87 $1.09 - $1.36 155,000 $ 1.26 9.4 25,000 $ 1.36 $38.00 - $58.00 1,250 $ 55.20 8.7 1,115 $ 56.99 $100.00 - $197.00 19,996 $ 142.17 8.0 11,956 $ 144.84 $202.00 - $283.00 725 $ 250.69 7.3 451 $ 253.26 $311.00 - $358.00 1,875 $ 343.99 7.9 1,505 $ 346.28 $430.00 - $497.00 6,443 $ 454.44 6.4 4,935 $ 455.06 $501.00 - $567.00 3,139 $ 537.25 6.2 2,777 $ 536.54 $600.00 - $661.00 1,379 $ 601.64 5.1 1,379 $ 601.64 $700.00 - $792.00 1,937 $ 767.72 6.1 1,841 $ 767.15 $992.00 - $992.00 104 $ 992.00 2.3 104 $ 992.00 Total: 9,755,454 $ 1.96 9.1 1,969,073 $ 5.19 Restricted Stock Awards During the three nine September 30, 2020, no 2013 In June 2020, 250 June 2018. In July 2019, 378 2013 $38.08 378 In June 2019, 250 June 2018. In April 2019, 525 2013 $91.00 525 In January 2019, 3,625 2013 2018 2018 50% 50% nine September 30, 2020, 153 September 30, 2020, 2,217 zero As of September 30, 2020, 2,217 2017 The activity of the Company's 2017 nine September 30, 2020 The tenth 2017 January 1, 2020 March 31, 2020, 320 March 31, 2020 $0.59. The eleventh 2017 April 1, 2020 June 30, 2020, 300 June 30, 2020 $0.48. The twelfth 2017 “2017 July 1, 2020, September 30, 2020, 220 September 30, 2020 $0.44. In September 2020, 2017 twelfth September 30, 2020. As of September 30, 2020, 2017 252 The Company estimates the fair value of purchase rights under the ESPP using a Black-Scholes valuation model. The fair value of each purchase right was estimated on the date of grant using the Black-Scholes option valuation model and the straight-line attribution approach with the following weighted-average assumptions: Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Expected term (in years) 0.25 0.25 0.25 0.25 Average volatility 76% 98% 106% 84% Risk-free interest rate 0.14% 2.21% 0.66% 2.40% Dividend yield 0% 0% 0% 0% The weighted average grant date fair value of the purchase rights issued under the 2017 three nine September 30, 2020, $0.17 $0.29, 2017 three nine September 30, 2019 $13.16 $2.12, Stock-Based Compensation During the three September 30, 2020, 550,000 $0.36 no three September 30, 2019. three September 30, 2020, 1,018,000 $0.44 nine September 30, 2019, 23,069 $117.86. no three nine September 30, 2020 2019. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee and nonemployee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Expected term (in years) 5 N/A 5 5 Average volatility 87% N/A 81% 73% Risk-free interest rate 0.27% N/A 0.34% 2.49% Dividend yield - N/A - - Option-pricing models require the input of various subjective assumptions, including the option's expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company's stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies' stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three nine September 30, 2020 2019 Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Cost of revenue $ 42 $ 25 $ 163 $ 91 Research and development 78 41 250 134 Selling, general and administrative 522 452 1,596 1,409 Total $ 642 $ 518 $ 2,009 $ 1,634 As of September 30, 2020, $5,469,000. 2.6

Note 13 - Income Taxes

Note 13 - Income Taxes	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. Income Taxes No no For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company's effective tax rate is 0% three nine September 30, 2020. 2020 0% The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020

Note 14 - Related Party Transac

Note 14 - Related Party Transactions	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	14. Related Party Transactions In June 2006, October 4, 2007. 300 September 30, 2020, 855 375 $199,000 $720,000 three September 30, 2020 2019, $948,000 $3,853,000 nine September 2020 2019, September 30, 2020 December 31, 2019 $1,000 $124,000, In August 2017, February 2019, no

Note 15 - Restructuring Costs

Note 15 - Restructuring Costs	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	15. Restructuring Costs In January 2019, 40 $742,000 first 2019

Note 16 - Subsequent Events

Note 16 - Subsequent Events	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	16. Subsequent Events In October 2020, 8 24 six 10 16 no two

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Reserve Stock Split, Policy [Policy Text Block]	Reverse Stock Split The Company effected a 1 100 September 18, 2019. not No The par value of the Company's common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75,000,000. The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company's equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company's products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three September 30, 2020, one 40% three September 30, 2019, two 31% nine September 30, 2020, one 45% nine September 30, 2019, one 17% There were no 10% three nine September 30, 2020 2019. As of September 30, 2020, one 16% December 31, 2019, two 49%
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $566,000 September 30, 2020 $407,000 December 31, 2019. There were no three September 30, 2020. nine September 30, 2020, $173,000 no three nine September 30, 2019.
Revenue from Contract with Customer [Policy Text Block]	Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company's operating leases for the Viveve System generally have a rental period of six nine June 30, 2019. three September 30, 2020 2019, $471,000 $177,000, nine September 30, 2020 2019, $829,000 $177,000, September 30, 2020 December 31, 2019, $617,000 $662,000, three nine September 30, 2020, $197,000 $499,000, December 31, 2019. Late in the first 2020, 19 70 80% three 19 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No September 30, 2020 December 31, 2019. $0 $108,000, not September 30, 2020 December 31, 2019, three nine September 30, 2020, $21,000 $108,000, December 31, 2019. The following table reflects the changes in our customer contract liabilities for the nine September 30, 2020: September 30, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ - $ 108 $ (108 ) Total $ - $ 108 $ (108 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three nine September 30, 2020 2019, not Contract Costs The Company began its rental program in the quarter ended June 30, 2019. $55,000 $337,000 September 30, 2020 December 31, 2019, three September 30, 2020 2019, $58,000 $30,000, nine September 30, 2020 2019, $538,000 $30,000, no one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company's financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three nine September 30, 2020 2019 Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 United States $ 844 $ 652 $ 1,648 $ 3,106 Asia Pacific 680 373 1,865 1,684 Europe and Middle East - 27 5 316 Latin America - - 14 10 Total $ 1,524 $ 1,052 $ 3,532 $ 5,116 The Company determines geographic location of its revenue based upon the destination of the shipments of its products.
Equity Method Investments [Policy Text Block]	Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee's business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three nine September 30, 2020 2019.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company's products sold to customers are generally subject to warranties between one three not
Share-based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee's service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option's expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three nine September 30, 2020 2019,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company's basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive: Nine Months Ended September 30, 2020 2019 Series B convertible preferred stock 22,702,614 (a) - Warrants to purchase common stock 17,710,876 5,549 Stock options to purchase common stock 9,755,454 50,471 Restricted common stock awards 2,217 3,432 (a) As of September 30, 2020, 34,735 22,702,614 1 653.59 $1,000 $1.53 not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued and Adopted Accounting Standards In November 2019, 2019 08, 718 606 718. December 15, 2019, January 1, 2020 not In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021, not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	September 30, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ - $ 108 $ (108 ) Total $ - $ 108 $ (108 )
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 United States $ 844 $ 652 $ 1,648 $ 3,106 Asia Pacific 680 373 1,865 1,684 Europe and Middle East - 27 5 316 Latin America - - 14 10 Total $ 1,524 $ 1,052 $ 3,532 $ 5,116
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Nine Months Ended September 30, 2020 2019 Series B convertible preferred stock 22,702,614 (a) - Warrants to purchase common stock 17,710,876 5,549 Stock options to purchase common stock 9,755,454 50,471 Restricted common stock awards 2,217 3,432

Note 5 - Accrued Liabilities (T

Note 5 - Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, December 31, 2020 2019 Deferred revenue - subscription rental program $ 617 $ 662 Accrued bonuses 589 726 Accrued payroll and other related expenses 335 839 Current operating lease liabilities 203 268 Accrued professional fees 133 592 Customer advances 21 53 Accrued sales commission 20 281 Accrued inventory - 474 Accrued interest 6 440 Customer contracts liabilities - 108 Other accruals 66 255 Total accrued liabilities $ 1,990 $ 4,698

Note 6 - Note Payable (Tables)

Note 6 - Note Payable (Tables)	9 Months Ended
	Sep. 30, 2020
The 2017 Loan Agreement [Member]
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2020 (remaining 3 months) $ - 2021 - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,605 ) Present value of obligations 4,387 Less: Unamortized debt discount (10 ) Note payable, noncurrent portion $ 4,377

Note 7 - Paycheck Protection _2

Note 7 - Paycheck Protection Program Loan (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Maturities of Long-term Debt [Table Text Block]	Year Ending December 31, 2020 (remaining 3 months) $ - 2021 938 2022 426 Total payments 1,364 Less: Amount representing interest (20 ) Present value of obligations 1,344 Paycheck Protection Program loan,current portion 664 Paycheck Protection Program loan, noncurrent portion $ 679

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Lessee, Lease Assets and Liabilities [Table Text Block]	September 30, December 31, 2020 2019 Assets: Operating lease right-of-use assets $ 200 $ 395 Liabilities: Current operating lease liabilities $ 203 $ 268 Noncurrent operating lease liabilities - 132 $ 203 $ 400
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending December 31, 2020 (remaining 3 months) $ 76 2021 137 Total lease payments 213 Less: Amount representing interest (10 ) Present value of lease liabilities $ 203
Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]	Year Ending December 31, 2020 (remaining 3 months) $ 381 2021 236 Thereafter - Total $ 617

Note 11 - Common Stock (Tables)

Note 11 - Common Stock (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 November 2019 Common Shares November 26, 2020 $ 0.61 423,809 November 2019 Common Shares November 26, 2024 $ 0.61 3,256,286 November 2019 Common Shares November 26, 2024 $ 1.836 9,893,776 April 2020 Common Shares April 21, 2025 $ 0.6371 4,132,084 17,710,876
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Immediately Immediately before Modification After Modification Exercise price $1.55 $0.61 Common stock price $0.63 $0.63 Expected term (in years) 2.8 2.8 Average volatility 97% 97% Risk-free interest rate 0.27% 0.27% Dividend yield 0% 0%

Note 12 - Summary of Stock Op_2

Note 12 - Summary of Stock Options (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Nine Months Ended September 30, 2020 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 10,087,678 $ 2.22 9.9 $ 3,928,715 Options granted 1,018,000 $ 0.70 Options exercised - Options canceled (1,350,224 ) $ 3.01 Options outstanding, end of period 9,755,454 $ 1.96 9.1 $ - Vested and exercisable and expected to vest, end of period 9,047,744 $ 2.03 9.1 $ - Vested and exercisable, end of period 1,969,073 $ 5.19 8.7 $ -
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices September 30, 2020 Price Term (Years) September 30, 2020 Price $0.52 - $0.89 9,563,606 $ 0.85 9.1 1,918,010 $ 0.87 $1.09 - $1.36 155,000 $ 1.26 9.4 25,000 $ 1.36 $38.00 - $58.00 1,250 $ 55.20 8.7 1,115 $ 56.99 $100.00 - $197.00 19,996 $ 142.17 8.0 11,956 $ 144.84 $202.00 - $283.00 725 $ 250.69 7.3 451 $ 253.26 $311.00 - $358.00 1,875 $ 343.99 7.9 1,505 $ 346.28 $430.00 - $497.00 6,443 $ 454.44 6.4 4,935 $ 455.06 $501.00 - $567.00 3,139 $ 537.25 6.2 2,777 $ 536.54 $600.00 - $661.00 1,379 $ 601.64 5.1 1,379 $ 601.64 $700.00 - $792.00 1,937 $ 767.72 6.1 1,841 $ 767.15 $992.00 - $992.00 104 $ 992.00 2.3 104 $ 992.00 Total: 9,755,454 $ 1.96 9.1 1,969,073 $ 5.19
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Expected term (in years) 5 N/A 5 5 Average volatility 87% N/A 81% 73% Risk-free interest rate 0.27% N/A 0.34% 2.49% Dividend yield - N/A - -
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Cost of revenue $ 42 $ 25 $ 163 $ 91 Research and development 78 41 250 134 Selling, general and administrative 522 452 1,596 1,409 Total $ 642 $ 518 $ 2,009 $ 1,634
2017 Employee Stock Purchase Plan [Member]
Notes Tables
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2020 2019 2020 2019 Expected term (in years) 0.25 0.25 0.25 0.25 Average volatility 76% 98% 106% 84% Risk-free interest rate 0.14% 2.21% 0.66% 2.40% Dividend yield 0% 0% 0% 0%

Note 1 - The Company and Basi_2

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Jun. 09, 2020	Jun. 08, 2020	Apr. 20, 2020	Apr. 16, 2020	Nov. 26, 2019	Nov. 12, 2019	Sep. 30, 2020	Aug. 31, 2020	Jun. 30, 2020	May 31, 2020	Feb. 29, 2020	Nov. 30, 2019	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Nov. 30, 2019	Apr. 15, 2020	Dec. 31, 2019
Proceeds from Warrant Exercises																	$ 8,407,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							17,710,876						17,710,876				17,710,876
Payments of Warrant Issuance Costs			$ 333,000														$ 333,000
Retained Earnings (Accumulated Deficit), Ending Balance							$ (215,071,000)						$ (215,071,000)				(215,071,000)				$ (197,911,000)	[1]
Cash and Cash Equivalents, at Carrying Value, Ending Balance							9,200,000						9,200,000				9,200,000				$ 13,308,000	[1]
Working Capital							$ 12,895,000						12,895,000				12,895,000
Net Cash Provided by (Used in) Operating Activities, Total																	(12,936,000)	(25,862,000)
Net Cash Provided by (Used in) Financing Activities, Total													$ 3,600,000				$ 9,231,000	$ 6,273,000
Conversion of Term Loan with CRG Into Stock and Warrants [Member]
Debt Conversion, Original Debt, Amount						$ 28,981,000
Debt Conversion, Converted Instrument, Amount						$ 31,300,000
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)					31,300	31,300
Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)																	5,473,410
Preferred Stock, Shares Outstanding, Ending Balance (in shares)							0		0				0	0			0				1,852,173
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)							1					1	1				1		1
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)							0						0				0
Series B Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)							34,735						34,735				34,735				31,678	[2]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)							22,702,614						22,702,614				22,702,614
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)														525,000		1,004,171
Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																				$ 0.61	$ 1.55
Proceeds from Warrant Exercises				$ 3,089,000
Series A Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 1.55							$ 1.55
Stock Issued During Period, Shares, Warrant Exercises (in shares)				4,820,584				1,117,020	27,601	4,099	1,026,240
Proceeds from Warrant Exercises								$ 681,000	$ 17,000	$ 2,500	$ 1,591,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							423,809					7,419,353	423,809				423,809		7,419,353
Warrants and Rights Outstanding, Term (Year)												1 year							1 year
Series A Warrants [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)													1,117,020	4,852,284	1,026,240
Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 1.55							$ 1.55
Stock Issued During Period, Shares, Warrant Exercises (in shares)				242,790			15,000	3,809,104	50,700		45,473
Proceeds from Warrant Exercises							$ 9,000	$ 2,324,000	$ 31,000		$ 70,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							3,256,286					7,419,353	3,256,286				3,256,286		7,419,353
Warrants and Rights Outstanding, Term (Year)												5 years							5 years
Series B Warrants [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)													3,824,104	293,490	45,473
Series A-2 Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)								892,300									3,928,284
Proceeds from Warrant Exercises								$ 569,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			4,820,584				3,928,284						3,928,284				3,928,284
Series A-2 Warrants [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)													892,300
Series B-2 Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)								38,900									203,800
Proceeds from Warrant Exercises								$ 25,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			242,790				203,800						203,800				203,800
Series B-2 Warrants [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)													38,990
Series A-2 and Series B-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.6371
Warrants and Rights Outstanding, Term (Year)			5 years
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					9,893,776	9,893,776
Warrants and Rights Outstanding, Term (Year)						5 years
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)							9,893,776						9,893,776				9,893,776
Purchase Agreement with LPC [Member]
Maximum Amount of Shares Issuable	$ 10,000,000	$ 10,000,000
Stock Purchase Agreement Duration Period (Month)	2 years 180 days	2 years 180 days
Stock Issued During Period, Shares, New Issues (in shares)	525,000
Shares Issued, Price Per Share (in dollars per share)	$ 0.65
Maximum Number of Shares Issuable on Any Business Day Selected by The Company (in shares)	250,000
Maximum Number of Shares Issuable on Any Business Day Selected by The Company in Certain Circumstances (in shares)	500,000
November 2019 Offering [Member]
Proceeds from Issuance or Sale of Equity, Total												$ 11,500,000
Proceeds From Issuance of Common Stock, Net												$ 9,922,000
November 2019 Offering [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)												5,473,410
November 2019 Offering [Member] | Series B Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)																			5,473,410
November 2019 Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)												1,945,943							1,945,943
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.
[2]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Sep. 18, 2019	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)$ / sharesshares
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares		$ 0.0001			$ 0.0001		$ 0.0001	[1]
Common Stock, Shares Authorized (in shares) | shares		75,000,000			75,000,000		75,000,000	[1]
Number of Financial Institutions		1			1
Accounts Receivable, Allowance for Credit Loss, Ending Balance		$ 566,000			$ 566,000		$ 407,000
Accounts Receivable, Allowance for Credit Loss, Writeoff		0	$ 0		173,000	$ 0
Revenue from Contract with Customer, Excluding Assessed Tax, Total		1,524,000	1,052,000		3,532,000	5,116,000
Deferred Income		617,000			617,000		662,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total		0			0		0
Contract with Customer, Liability, Total							108,000
Capitalized Contract Cost, Net, Total		55,000			55,000		$ 337,000
Capitalized Contract Cost, Amortization		58,000	30,000		538,000	30,000
Capitalized Contract Cost, Impairment Loss					0
Equity Method Investment, Other than Temporary Impairment		$ 0	0	$ 0	$ 0
Series B Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares		34,735			34,735		31,678	[1]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares		22,702,614			22,702,614
Conversion of Stock Exchange Ratio					653.59
Preferred Stock, Liquidation Preference Per Share (in dollars per share) | $ / shares		$ 1,000			$ 1,000
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares		$ 1.53			$ 1.53
Minimum [Member]
Warranty Period (Year)					1 year
Maximum [Member]
Warranty Period (Year)					3 years
Rental [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total		$ 471,000	$ 177,000		$ 829,000	$ 177,000
Rental Program Equipment [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total		197,000			499,000
Marketing Programs [Member]
Contract with Customer, Liability, Total		0			0		$ 108,000
Contract with Customer, Liability, Revenue Recognized		$ 21,000			$ 108,000
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Number of Customers		1	2		1	1
Concentration Risk, Percentage		40.00%	31.00%		45.00%	17.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers					1		2
Concentration Risk, Percentage					16.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage							49.00%
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	100
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Customer Contract Liabilities (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Customer contract liabilities		$ 108,000
Change in customer contract liabilities	(108,000)
Marketing Programs [Member]
Customer contract liabilities	0	$ 108,000
Change in customer contract liabilities	$ (108,000)

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue	$ 1,524	$ 1,052	$ 3,532	$ 5,116
North America [Member]
Revenue	844	652	1,648	3,106
Asia Pacific [Member]
Revenue	680	373	1,865	1,684
Europe And Middle East [Member]
Revenue		27	5	316
Latin America [Member]
Revenue			$ 14	$ 10

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2020		Sep. 30, 2019
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	22,702,614	[1]
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	17,710,876		5,549
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	9,755,454		50,471
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	2,217		3,432
[1]	As of September 30, 2020, a total of 34,735 shares of Series B convertible preferred stock were outstanding and are convertible into 22,702,614 shares of common stock. Each share of Series B convertible preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1-for-653.59 per share determined by dividing the Series B liquidation amount of $1,000 per share by the Series B conversion price of $1.53 per share. However, under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not convert the Series B preferred stock or exercise the CRG warrants until the Company's stockholders act to authorize additional number of shares of common stock sufficient to cover the conversion shares.

Note 4 - Investment in Limite_2

Note 4 - Investment in Limited Liability Company (Details Textual)	Aug. 08, 2017USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2019USD ($)
Income (Loss) from Equity Method Investments, Total		$ (55,000)	$ (168,000)	$ (323,000)	$ (431,000)
InControl Medical [Member]
Equity Method Investment, Ownership Percentage		7.00%		7.00%		7.00%
Income (Loss) from Equity Method Investments, Total		$ (55,000)	$ (168,000)	$ (323,000)	$ (431,000)
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased		185	0	425	300	5,225
Unrecorded Unconditional Purchase Obligation, Purchases		$ 26,000	$ 0	$ 46,000	$ 27,000
Payments for Purchase of Products		10,000	$ 0	30,000	$ 27,000
Accounts Payable, Related Parties, Current		$ 16,000		$ 16,000		$ 16,000	$ 0
Payments to Acquire Equity Method Investments	$ 2,500,000

Note 5 - Accrued Liabilities -

Note 5 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Deferred revenue - subscription rental program	$ 617	$ 662
Accrued bonuses	589	726
Accrued payroll and other related expenses	335	839
Accrued professional fees	133	592
Accrued sales commission	20	281
Accrued inventory		474
Accrued interest	6	440
Other accruals	66	255
Total accrued liabilities	1,990	4,698	[1]
Customer Advances [Member]
Contract with customer, liability	21	53
Customer Contracts Liabilites [Member]
Contract with customer, liability		108
Accrued Liabilities [Member]
Current operating lease liabilities	$ 203	$ 268
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Note 6 - Note Payable (Details

Note 6 - Note Payable (Details Textual) - USD ($)	Nov. 26, 2019	Nov. 12, 2019	Dec. 29, 2017	May 22, 2017	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					17,710,876		17,710,876
Notes Payable, Noncurrent, Total					$ 4,377,000		$ 4,377,000		$ 3,983,000	[1]
Gains (Losses) on Restructuring of Debt									(6,705,000)
Series B Preferred Stock [Member]
Conversion of Stock, Conversion Rate (in dollars per share)					$ 1.53		$ 1.53
Preferred Stock, Fair Value, Per Share (in dollars per share)	$ 1,023.23
Convertible Preferred Stock, Fair Value	$ 32,027,000
Minimum [Member] | Series B Convertible Preferred Stock Into Common Stock [Member]
Conversion of Stock, Conversion Rate (in dollars per share)		$ 1.53
Maximum [Member] | Series B Convertible Preferred Stock Into Common Stock [Member]
Conversion of Stock, Conversion Rate (in dollars per share)		$ 1.836
Conversion of Term Loan with CRG Into Stock and Warrants [Member]
Debt Conversion, Original Debt, Amount		$ 28,981,000
Debt Conversion, Converted Instrument, Amount		$ 31,300,000
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	31,300	31,300
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Warrants and Rights Outstanding, Term (Year)				10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				2,220
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 950
Warrants and Rights Outstanding				$ 940,000
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	9,893,776	9,893,776
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate		120.00%
Warrants and Rights Outstanding		$ 3,502,000			$ 3,502,000		$ 3,502,000
The 2017 Loan Agreement [Member]
Notes Payable, Noncurrent, Total					4,377,000		4,377,000
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Instrument, Face Amount				20,000,000
Debt Agreement, Covenant, Additional Funding				10,000,000
Debt Agreement, Maximum Borrowing Capacity				$ 30,000,000
Proceeds from Lines of Credit, Total			$ 10,000,000
Debt Instrument, Term (Year)				6 years
Debt instrument, Interest Only Payment, Period (Year)				4 years
Debt Instrument, Interest Rate, Stated Percentage				12.50%
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period				4.00%
Paid-in-Kind Interest					136,000	$ 331,000	392,000	$ 973,000
Debt Instrument, Prepayment Fee, Percentage				5.00%
Debt Instrument, Back-end Facility Fee Percentage of Principal		25.00%		5.00%
Notes Payable, Noncurrent, Total					$ 4,377,000		$ 4,377,000		$ 3,983,000
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Note 6 - Note Payable - Summary

Note 6 - Note Payable - Summary of Note Payable (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019	[1]
Less: Unamortized debt discount	$ (10,000)
Note payable, noncurrent portion	4,377,000	$ 3,983,000
The 2017 Loan Agreement [Member]
2020 (remaining 3 months)
2021
2022
2023	5,992,000
Total payments	5,992,000
Less: Amount representing interest	(1,605,000)
Present value of obligations	4,387,000
Less: Unamortized debt discount	(10,000)
Note payable, noncurrent portion	$ 4,377,000
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Note 7 - Paycheck Protection _3

Note 7 - Paycheck Protection Program Loan (Details Textual) - USD ($)	Apr. 24, 2020	Sep. 30, 2020	Sep. 30, 2019
Proceeds from Issuance of Unsecured Debt		$ 1,343,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Unsecured Debt	$ 1,343,000

Note 7 - Paycheck Protection _4

Note 7 - Paycheck Protection Program Loan - Summary of Paycheck Protection Program Loan (Details) - Paycheck Protection Program CARES Act [Member] $ in Thousands	Sep. 30, 2020USD ($)
2020 (remaining 3 months)
2021	938
2022	426
Total payments	1,364
Less: Amount representing interest	(20)
Present value of obligations	1,344
Paycheck Protection Program loan,current portion	664
Paycheck Protection Program loan, noncurrent portion	$ 679

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2018USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Feb. 01, 2017USD ($)ft²
Operating Lease, Expense		$ 77,000	$ 75,000	$ 226,000	$ 225,000
Operating Lease, Weighted Average Discount Rate, Percent		12.50%		12.50%
Operating Lease, Property Plant and Equipment, Amount		$ 946,000		$ 946,000
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property (Square Foot) | ft²						12,400
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year						20.5
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year						21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year						21.75
Security Deposit						$ 22,000
Operating Leases, Allowance for Certain Improvements						$ 88,000
Noncancelable Operating Lease Agreement for Office Equipment [Member]
Lessee, Operating Lease, Term of Contract (Month)	3 years
Operating Leases, Monthly Payment	$ 3,000
Leases of Viveve Systems [Member]
Lessor, Operating Lease, Depreciation on Leased Assets		$ 117,000		$ 345,000

Note 8 - Leases - Lease Assets

Note 8 - Leases - Lease Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Operating lease right-of-use assets	$ 200	$ 395
Accrued Liabilities [Member]
Current operating lease liabilities	203	268
Other Noncurrent Liabilities [Member]
Noncurrent operating lease liabilities		132
Accrued Liabilities and Other Noncurrent Liabilities [Member]
Operating Lease, Liability, Total	$ 203	$ 400

Note 8 - Leases - Maturity of O

Note 8 - Leases - Maturity of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
2020 (remaining 3 months)	$ 76
2021	137
Total lease payments	213
Less: Amount representing interest	(10)
Accrued Liabilities and Other Noncurrent Liabilities [Member]
Present value of lease liabilities	$ 203	$ 400

Note 8 - Leases - Minimum Futur

Note 8 - Leases - Minimum Future Rentals (Details) $ in Thousands	Sep. 30, 2020USD ($)
2020 (remaining 3 months)	$ 381
2021	236
Thereafter
Total	$ 617

Note 10 - Preferred Stock (Deta

Note 10 - Preferred Stock (Details Textual) - USD ($)	Nov. 26, 2019	Nov. 12, 2019	Feb. 29, 2020	Jan. 31, 2020	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019		Jun. 30, 2020	Nov. 30, 2019
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					17,710,876	17,710,876
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)					9,893,776	9,893,776
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	9,893,776	9,893,776
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	31,300	31,300
Series A Convertible Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)			669,022	1,183,151
Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)					1	1				1
Stock Issued During Period, Shares, New Issues (in shares)						5,473,410
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					0	0	1,852,173		0
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					0	0
Series B Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)					22,702,614	22,702,614
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					34,735	34,735	31,678	[1]
Preferred Stock, Dividend Rate, Percentage	12.50%
Preferred Stock Dividends, Shares (in shares)					1,050	3,057	378
Dividends, Preferred Stock, Cash					$ 3,000	$ 7,000	$ 2,000
Preferred Stock, Fair Value, Per Share (in dollars per share)	$ 1,023.23
Convertible Preferred Stock, Fair Value	$ 32,027,000
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)	31,300
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Note 11 - Common Stock (Details

Note 11 - Common Stock (Details Textual)	Jun. 09, 2020USD ($)$ / sharesshares	Jun. 08, 2020USD ($)	Apr. 20, 2020USD ($)$ / sharesshares	Apr. 16, 2020USD ($)shares	Sep. 30, 2020USD ($)$ / sharesshares	Aug. 31, 2020USD ($)shares	Jun. 30, 2020USD ($)shares	May 31, 2020USD ($)shares	Mar. 31, 2020USD ($)shares	Feb. 29, 2020USD ($)shares	Nov. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2020USD ($)shares	Mar. 31, 2020USD ($)shares	Sep. 30, 2019USD ($)shares	Mar. 31, 2019USD ($)shares	Jun. 30, 2020USD ($)shares	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)shares	Nov. 30, 2019$ / sharesshares	Apr. 15, 2020$ / shares	Dec. 31, 2019$ / sharesshares		Nov. 26, 2019shares	Nov. 12, 2019USD ($)$ / sharesshares	May 22, 2017USD ($)$ / sharesshares
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					17,710,876							17,710,876						17,710,876
Stock Issued During Period, Share, Restricted Common Shares (in shares)					47,090		34,531		28,313
Stock Issued During Period, Value, Restricted Common Shares | $					$ 25,000		$ 25,000		$ 24,000				$ 25,000	$ 24,000		$ 25,000
Proceeds from Warrant Exercises | $																		$ 8,407,000
Fair Value Adjustment of Warrants | $																	$ 1,838,000	1,838,000
Payments of Warrant Issuance Costs | $			$ 333,000															333,000
Amortization of Debt Discount (Premium) | $												1,000			$ 119,000			2,000	$ 202,000
Debt Instrument, Unamortized Discount, Total | $					10,000							$ 10,000						$ 10,000
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period (in shares)												0			0				0
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Expired In Period (in shares)												0			859			215	859
The 2017 Loan Agreement [Member]
Debt Issuance Costs, Net, Total | $							$ 790,000						$ 790,000				$ 790,000
Debt Instrument, Unamortized Discount, Total | $					$ 10,000							$ 10,000						$ 10,000
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member]
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares																									$ 1.53
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member]
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares																									$ 1.836
Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)																		5,473,410
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)					1						1	1						1		1
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					0		0					0	0				0	0				1,852,173
Series B Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)					22,702,614							22,702,614						22,702,614
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					34,735							34,735						34,735				31,678	[1]
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares					$ 1.53							$ 1.53						$ 1.53
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)											1									1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 1.55									$ 1.55
Warrants and Rights Outstanding, Term (Year)											1 year									1 year
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					423,809						7,419,353	423,809						423,809		7,419,353
Stock Issued During Period, Shares, Warrant Exercises (in shares)				4,820,584		1,117,020	27,601	4,099		1,026,240
Proceeds from Warrant Exercises | $						$ 681,000	$ 17,000	$ 2,500		$ 1,591,000
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)											1									1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 1.55									$ 1.55
Warrants and Rights Outstanding, Term (Year)											5 years									5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					3,256,286						7,419,353	3,256,286						3,256,286		7,419,353
Stock Issued During Period, Shares, Warrant Exercises (in shares)				242,790	15,000	3,809,104	50,700			45,473
Proceeds from Warrant Exercises | $					$ 9,000	$ 2,324,000	$ 31,000			$ 70,000
Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																					$ 0.61	$ 1.55
Proceeds from Warrant Exercises | $				$ 3,089,000
Series A-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			4,820,584		3,928,284							3,928,284						3,928,284
Stock Issued During Period, Shares, Warrant Exercises (in shares)						892,300												3,928,284
Proceeds from Warrant Exercises | $						$ 569,000
Series B-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			242,790		203,800							203,800						203,800
Stock Issued During Period, Shares, Warrant Exercises (in shares)						38,900												203,800
Proceeds from Warrant Exercises | $						$ 25,000
Series A-2 and Series B-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 0.6371
Warrants and Rights Outstanding, Term (Year)			5 years
Class of Warrant or Right, Outstanding (in shares)			1,838,000
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input			0
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input			0.841
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input			0.0035
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input			5
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Warrants and Rights Outstanding, Term (Year)																									5 years
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)					9,893,776							9,893,776						9,893,776
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																								9,893,776	9,893,776
Class of Warrants or Rights, Outstanding, Percentage of Common Stock																									15.00%
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate																									120.00%
Warrants and Rights Outstanding | $					$ 3,502,000							$ 3,502,000						$ 3,502,000							$ 3,502,000
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input																									0
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input																									0.688
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input																									0.0158
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input																									5
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																										$ 950
Warrants and Rights Outstanding, Term (Year)																										10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																										2,220
Warrants and Rights Outstanding | $																										$ 940,000
Class A Units [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)											1									1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 1.55									$ 1.55
Warrants and Rights Outstanding, Term (Year)											1 year									1 year
Class A Units [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)											1									1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 1.55									$ 1.55
Warrants and Rights Outstanding, Term (Year)											5 years									5 years
Class B Units [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)											1									1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 1.55									$ 1.55
Warrants and Rights Outstanding, Term (Year)											1 year									1 year
Class B Units [Member] | Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)											1									1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 1.55									$ 1.55
Warrants and Rights Outstanding, Term (Year)											5 years									5 years
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)													525,000		1,004,171
Stock Issued During Period, Share, Restricted Common Shares (in shares)													34,531	28,313		274
Stock Issued During Period, Value, Restricted Common Shares | $
Common Stock [Member] | Series A Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)												1,117,020	4,852,284	1,026,240
Common Stock [Member] | Series B Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)												3,824,104	293,490	45,473
Common Stock [Member] | Series A-2 Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)												892,300
Common Stock [Member] | Series B-2 Warrants [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)												38,990
Purchase Agreement with LPC [Member]
Maximum Amount of Shares Issuable | $	$ 10,000,000	$ 10,000,000
Stock Purchase Agreement Duration Period (Month)	2 years 180 days	2 years 180 days
Stock Issued During Period, Shares, New Issues (in shares)	525,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 0.65
Maximum Number of Shares Issuable on Any Business Day Selected by The Company (in shares)	250,000
Maximum Number of Shares Issuable on Regular Purchase, Closing Sale Price Not Below $1.00 (in shares)	300,000
Maximum Number of Shares Issuable on Regular Purchase, Closing Sale Price Not Below $2.00 (in shares)	500,000
Maximum Number of Shares Issuable Any single Regular Purchase (in shares)	1,000,000
Payments of Stock Issuance Costs | $	$ 494,000																	494,000
Purchase Agreement with LPC [Member] | Commitment Fee [Member]
Payments of Stock Issuance Costs | $	$ 325,000
November 2019 Offering [Member]
Payments of Stock Issuance Costs | $																		$ 33,000
Proceeds from Issuance or Sale of Equity, Total | $											$ 11,500,000
Proceeds From Issuance of Common Stock, Net | $											$ 9,922,000
November 2019 Offering [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)											5,473,410
November 2019 Offering [Member] | Series B Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)																				5,473,410
November 2019 Offering [Member] | Class A Units [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares											$ 1.55									$ 1.55
Common Shares Per Unit (in shares)											1									1
November 2019 Offering [Member] | Class B Units [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares											$ 1.55									$ 1.55
Series A Convertible Preferred Stock Per Unit (in shares)											1									1
November 2019 Offering [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)											1,945,943									1,945,943
[1]	The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date.

Note 11 - Common Stock - Summar

Note 11 - Common Stock - Summary of Outstanding Warrants (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Shares Outstanding Under Warrants (in shares)	17,710,876
Warrant One [Member]
Expiration Date	Feb. 17, 2025
Exercise Price (in dollars per share) | $ / shares	$ 400
Shares Outstanding Under Warrants (in shares)	754
Warrant Two [Member]
Expiration Date	Mar. 26, 2025
Exercise Price (in dollars per share) | $ / shares	$ 272
Shares Outstanding Under Warrants (in shares)	14
Warrant Three [Member]
Expiration Date	May 12, 2025
Exercise Price (in dollars per share) | $ / shares	$ 424
Shares Outstanding Under Warrants (in shares)	362
Warrant Four [Member]
Expiration Date	Dec. 16, 2025
Exercise Price (in dollars per share) | $ / shares	$ 560
Shares Outstanding Under Warrants (in shares)	267
Warrant Five [Member]
Expiration Date	Apr. 1, 2026
Exercise Price (in dollars per share) | $ / shares	$ 608
Shares Outstanding Under Warrants (in shares)	250
Warrant Six [Member]
Expiration Date	May 11, 2021
Exercise Price (in dollars per share) | $ / shares	$ 774
Shares Outstanding Under Warrants (in shares)	50
Warrant Seven [Member]
Expiration Date	Jun. 20, 2026
Exercise Price (in dollars per share) | $ / shares	$ 498
Shares Outstanding Under Warrants (in shares)	1,004
Warrant Eight [Member]
Expiration Date	May 25, 2027
Exercise Price (in dollars per share) | $ / shares	$ 950
Shares Outstanding Under Warrants (in shares)	2,220
Warrant Nine [Member]
Expiration Date	Nov. 26, 2020
Exercise Price (in dollars per share) | $ / shares	$ 0.61
Shares Outstanding Under Warrants (in shares)	423,809
Warrant Ten [Member]
Expiration Date	Nov. 26, 2024
Exercise Price (in dollars per share) | $ / shares	$ 0.61
Shares Outstanding Under Warrants (in shares)	3,256,286
Warrant Eleven [Member]
Expiration Date	Nov. 26, 2024
Exercise Price (in dollars per share) | $ / shares	$ 1.836
Shares Outstanding Under Warrants (in shares)	9,893,776
Warrant Twelve [Member]
Expiration Date	Apr. 21, 2025
Exercise Price (in dollars per share) | $ / shares	$ 0.6371
Shares Outstanding Under Warrants (in shares)	4,132,084

Note 11 - Common Stock - Assump

Note 11 - Common Stock - Assumptions (Details) - Warrant [Member]	Apr. 15, 2020	Apr. 14, 2020
Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input	0.61	1.55
Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	0.63	0.63
Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	2.8	2.8
Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.0097	0.0094
Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.000027	0.000027
Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0

Note 12 - Summary of Stock Op_3

Note 12 - Summary of Stock Options (Details Textual) - USD ($)	Jan. 01, 2020	Jun. 30, 2020	Jul. 31, 2019	Jun. 30, 2019	Apr. 30, 2019	Jan. 31, 2019	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Nov. 26, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)							9,755,454					9,755,454		10,087,678
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)							$ 1.96					$ 1.96		$ 2.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)												9 years 36 days		9 years 328 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)												1,018,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Consultant [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)		250		250
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)					525
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)			378		525
Restricted Stock [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 38.08		$ 91
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate												0.00%
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total							$ 5,469,000					$ 5,469,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)												2 years 219 days
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)							104					104
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)							0					0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)							$ 992					$ 992
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)												2 years 109 days
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)							9,755,350					9,755,350
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)							4,770,640					4,770,640
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)							$ 1.95					$ 1.95
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)												9 years 36 days
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	2,639,926
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	14,512,457														11,872,531
The 2013 Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)							550,000			0		1,018,000	23,069
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)							$ 0.36					$ 0.44	$ 117.86
The 2013 Plan [Member] | Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)							0			0		0	0
The 2013 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)						3,625	0					0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)												153
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)											0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)							2,217					2,217
2017 Employee Stock Purchase Plan [Member]
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)							220	300	320
Shares Issued, Price Per Share (in dollars per share)		$ 0.48					$ 0.44	$ 0.48	$ 0.59		$ 0.48	$ 0.44
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares (in shares)							252					252
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased (in dollars per share)							$ 0.17			$ 13.16		$ 0.29	$ 2.12
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate							0.00%			0.00%		0.00%	0.00%

Note 12 - Summary of Stock Op_4

Note 12 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares
Options outstanding, beginning of period (in shares) | shares	10,087,678
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 2.22
Options outstanding, weighted average remaining contractual term (Year)	9 years 36 days	9 years 328 days
Options outstanding, aggregate intrinsic value | $		$ 3,928,715
Options granted (in shares) | shares	1,018,000
Options granted, weighted average exercise price (in dollars per share) | $ / shares	$ 0.70
Options exercised (in shares) | shares
Options exercised, weighted average exercise price (in dollars per share) | $ / shares
Options canceled (in shares) | shares	(1,350,224)
Options canceled, weighted average exercise price (in dollars per share) | $ / shares	$ 3.01
Options outstanding, end of period (in shares) | shares	9,755,454	10,087,678
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 1.96	$ 2.22
Vested and exercisable and expected to vest, end of period (in shares) | shares	9,047,744
Vested and exercisable and expected to vest, end of period, weighted average exercise price (in dollars per share) | $ / shares	$ 2.03
Vested and exercisable and expected to vest, end of period, weighted average remaining contractual term (Year)	9 years 36 days
Vested and exercisable and expected to vest, end of period, aggregate intrinsic value | $
Vested and exercisable, end of period (in shares) | shares	1,969,073
Vested and exercisable, end of period, weighted average exercise price (in dollars per share) | $ / shares	$ 5.19
Vested and exercisable, end of period, weighted average remaining contractual term (Year)	8 years 255 days
Vested and exercisable, end of period, aggregate intrinsic value | $

Note 12 - Summary of Stock Op_5

Note 12 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Options outstanding, number (in shares) | shares	9,755,454
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.96
Options outstanding, weighted average remaining contractual term (Year)	9 years 36 days
Options exercisable, number exercisable (in shares) | shares	1,969,073
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.19
Range One [Member]
Exercise price range, lower limit (in dollars per share)	0.52
Exercise price range, upper limit (in dollars per share)	$ 0.89
Options outstanding, number (in shares) | shares	9,563,606
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.85
Options outstanding, weighted average remaining contractual term (Year)	9 years 36 days
Options exercisable, number exercisable (in shares) | shares	1,918,010
Options exercisable, weighted average exercise price (in dollars per share)	$ 0.87
Range Two [Member]
Exercise price range, lower limit (in dollars per share)	1.09
Exercise price range, upper limit (in dollars per share)	$ 1.36
Options outstanding, number (in shares) | shares	155,000
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.26
Options outstanding, weighted average remaining contractual term (Year)	9 years 146 days
Options exercisable, number exercisable (in shares) | shares	25,000
Options exercisable, weighted average exercise price (in dollars per share)	$ 1.36
Range Three [Member]
Exercise price range, lower limit (in dollars per share)	38
Exercise price range, upper limit (in dollars per share)	$ 58
Options outstanding, number (in shares) | shares	1,250
Options outstanding, weighted average exercise price (in dollars per share)	$ 55.20
Options outstanding, weighted average remaining contractual term (Year)	8 years 255 days
Options exercisable, number exercisable (in shares) | shares	1,115
Options exercisable, weighted average exercise price (in dollars per share)	$ 56.99
Range Four [Member]
Exercise price range, lower limit (in dollars per share)	100
Exercise price range, upper limit (in dollars per share)	$ 197
Options outstanding, number (in shares) | shares	19,996
Options outstanding, weighted average exercise price (in dollars per share)	$ 142.17
Options outstanding, weighted average remaining contractual term (Year)	8 years
Options exercisable, number exercisable (in shares) | shares	11,956
Options exercisable, weighted average exercise price (in dollars per share)	$ 144.84
Range Five [Member]
Exercise price range, lower limit (in dollars per share)	202
Exercise price range, upper limit (in dollars per share)	$ 283
Options outstanding, number (in shares) | shares	725
Options outstanding, weighted average exercise price (in dollars per share)	$ 250.69
Options outstanding, weighted average remaining contractual term (Year)	7 years 109 days
Options exercisable, number exercisable (in shares) | shares	451
Options exercisable, weighted average exercise price (in dollars per share)	$ 253.26
Range Six [Member]
Exercise price range, lower limit (in dollars per share)	311
Exercise price range, upper limit (in dollars per share)	$ 358
Options outstanding, number (in shares) | shares	1,875
Options outstanding, weighted average exercise price (in dollars per share)	$ 343.99
Options outstanding, weighted average remaining contractual term (Year)	7 years 328 days
Options exercisable, number exercisable (in shares) | shares	1,505
Options exercisable, weighted average exercise price (in dollars per share)	$ 346.28
Range Seven [Member]
Exercise price range, lower limit (in dollars per share)	430
Exercise price range, upper limit (in dollars per share)	$ 497
Options outstanding, number (in shares) | shares	6,443
Options outstanding, weighted average exercise price (in dollars per share)	$ 454.44
Options outstanding, weighted average remaining contractual term (Year)	6 years 146 days
Options exercisable, number exercisable (in shares) | shares	4,935
Options exercisable, weighted average exercise price (in dollars per share)	$ 455.06
Range Eight [Member]
Exercise price range, lower limit (in dollars per share)	501
Exercise price range, upper limit (in dollars per share)	$ 567
Options outstanding, number (in shares) | shares	3,139
Options outstanding, weighted average exercise price (in dollars per share)	$ 537.25
Options outstanding, weighted average remaining contractual term (Year)	6 years 73 days
Options exercisable, number exercisable (in shares) | shares	2,777
Options exercisable, weighted average exercise price (in dollars per share)	$ 536.54
Range Nine [Member]
Exercise price range, lower limit (in dollars per share)	600
Exercise price range, upper limit (in dollars per share)	$ 661
Options outstanding, number (in shares) | shares	1,379
Options outstanding, weighted average exercise price (in dollars per share)	$ 601.64
Options outstanding, weighted average remaining contractual term (Year)	5 years 36 days
Options exercisable, number exercisable (in shares) | shares	1,379
Options exercisable, weighted average exercise price (in dollars per share)	$ 601.64
Range Ten [Member]
Exercise price range, lower limit (in dollars per share)	700
Exercise price range, upper limit (in dollars per share)	$ 792
Options outstanding, number (in shares) | shares	1,937
Options outstanding, weighted average exercise price (in dollars per share)	$ 767.72
Options outstanding, weighted average remaining contractual term (Year)	6 years 36 days
Options exercisable, number exercisable (in shares) | shares	1,841
Options exercisable, weighted average exercise price (in dollars per share)	$ 767.15
Range Eleven [Member]
Exercise price range, lower limit (in dollars per share)	992
Exercise price range, upper limit (in dollars per share)	$ 992
Options outstanding, number (in shares) | shares	104
Options outstanding, weighted average exercise price (in dollars per share)	$ 992
Options outstanding, weighted average remaining contractual term (Year)	2 years 109 days
Options exercisable, number exercisable (in shares) | shares	104
Options exercisable, weighted average exercise price (in dollars per share)	$ 992

Note 12 - Summary of Stock Op_6

Note 12 - Summary of Stock Options - Valuation Assumption for Employee Stock Purchase Plan (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Expected term (Year)	5 years		5 years	5 years
Average volatility	87.00%		81.00%	73.00%
Risk-free interest rate	0.27%		0.34%	2.49%
Dividend yield
2017 Employee Stock Purchase Plan [Member]
Expected term (Year)	91 days	91 days	91 days	91 days
Average volatility	76.00%	98.00%	106.00%	84.00%
Risk-free interest rate	0.14%	2.21%	0.66%	2.40%
Dividend yield	0.00%	0.00%	0.00%	0.00%

Note 12 - Summary of Stock Op_7

Note 12 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Expected term (Year)	5 years	5 years	5 years
Average volatility	87.00%	81.00%	73.00%
Risk-free interest rate	0.27%	0.34%	2.49%
Dividend yield

Note 12 - Summary of Stock Op_8

Note 12 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Stock-based compensation expense	$ 642	$ 518	$ 2,009	$ 1,634
Cost of Sales [Member]
Stock-based compensation expense	42	25	163	91
Research and Development Expense [Member]
Stock-based compensation expense	78	41	250	134
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 522	$ 452	$ 1,596	$ 1,409

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($) xbrli-pure in Thousands, $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020
Income Tax Expense (Benefit), Total		$ 0
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%	0.00%
Forecast [Member]
Effective Income Tax Rate Reconciliation, Percent, Total			0.00%

Note 14 - Related Party Trans_2

Note 14 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($)	3 Months Ended		9 Months Ended		132 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Dec. 31, 2019
Stock Issued During Period, Shares, New Issues (in shares)					375
Related Party Transaction, Amounts of Transaction	$ 199,000	$ 720,000	$ 948,000	$ 3,853,000
Accounts Payable, Related Parties, Current	$ 1,000		$ 1,000		$ 1,000	$ 124,000

Note 15 - Restructuring Costs (

Note 15 - Restructuring Costs (Details Textual)	1 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)
Restructuring and Related Cost, Number of Positions Eliminated	40
Restructuring Charges, Total	$ 742,000				$ 742,000